Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes

Abstract Background The overlap between justice system involvement and drug use is well‐documented. Justice‐involved people who misuse opioids are at high risk for relapse and criminal recidivism. Criminal justice policymakers consider opioid‐specific medication‐assisted therapies (MATs) one approac...

Full description

Bibliographic Details
Main Authors: C. Clare Strange, Sarah M. Manchak, Jordan M. Hyatt, Damon M. Petrich, Alisha Desai, Cory P. Haberman
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Campbell Systematic Reviews
Online Access:https://doi.org/10.1002/cl2.1215
_version_ 1797990965679489024
author C. Clare Strange
Sarah M. Manchak
Jordan M. Hyatt
Damon M. Petrich
Alisha Desai
Cory P. Haberman
author_facet C. Clare Strange
Sarah M. Manchak
Jordan M. Hyatt
Damon M. Petrich
Alisha Desai
Cory P. Haberman
author_sort C. Clare Strange
collection DOAJ
description Abstract Background The overlap between justice system involvement and drug use is well‐documented. Justice‐involved people who misuse opioids are at high risk for relapse and criminal recidivism. Criminal justice policymakers consider opioid‐specific medication‐assisted therapies (MATs) one approach for improving outcomes for this population. More research is needed that explores the impacts of opioid‐specific MATs for justice‐involved people. Objectives This study sought to assess the effects of opioid‐specific MAT for reducing the frequency and likelihood of criminal justice and overdose outcomes for current or formerly justice‐involved individuals. Search Methods Records were searched between May 7, 2021 and June 23, 2021. We searched a total of sixteen proprietary and open access databases that included access to gray literature and conference proceedings. The bibliographies of included studies and relevant reviews were also searched. Selection Criteria Studies were eligible for inclusion in the review if they: (a) assessed the effects of opioid‐specific MATs on individual‐level criminal justice or overdose outcomes; included (b) a current or formerly justice‐involved sample; and (c) a randomized or strong quasi‐experimental design; and c) were published in English between January 1, 1960 and October 31, 2020. Data Collection and Analysis We used the standard methodological procedures as expected by The Campbell Collaboration. Main Results Twenty studies were included, representing 30,119 participants. The overall risk of bias for the experimental studies ranged from “some” to “high” and for quasi‐experimental studies ranged from “moderate” to “serious.” As such, findings must be interpreted against the backdrop of less‐than‐ideal methodological contexts. Of the 20 included studies, 16 included outcomes that were meta‐analyzed using mean log odds ratios (which were reported as mean odds ratios). Mean effects were nonsignificant for reincarceration (odds ratio [OR] = 0.93 [0.68, 1.26], SE = .16), rearrest (OR = 1.47 [0.70, 3.07], SE = 0.38), and fatal overdose (OR = 0.82 [0.56, 1.21], SE = 0.20). For nonfatal overdose, the average effect was significant (OR = 0.41 [0.18, 0.91], SE = 0.41, p < 0.05), suggesting that those receiving MAT had nearly 60% reduced odds of a nonfatal overdose. Implications for Policy, Practice, and Research The current review supports some utility for adopting MAT for the treatment of justice‐involved people with opioid addiction, however, more studies that employ rigorous methodologies are needed. Researchers should work with agencies to improve adherence to medication regimens, study design, and collect more detailed information on participants, their criminal and substance use histories, onset, and severity. This would help clarify whether treatment and control groups are indeed comparable and provide better insight into the potential reasons for participant dropout, treatment failure, and the occurrence of recidivism or overdose. Outcomes should be assessed in multiple ways, if possible (e.g., self‐report and official record), as reliance on official data alone may undercount participants' degree of criminal involvement.
first_indexed 2024-04-11T08:44:54Z
format Article
id doaj.art-095c44a0a3b6451485fad31608fcce3f
institution Directory Open Access Journal
issn 1891-1803
language English
last_indexed 2024-04-11T08:44:54Z
publishDate 2022-03-01
publisher Wiley
record_format Article
series Campbell Systematic Reviews
spelling doaj.art-095c44a0a3b6451485fad31608fcce3f2022-12-22T04:33:59ZengWileyCampbell Systematic Reviews1891-18032022-03-01181n/an/a10.1002/cl2.1215Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomesC. Clare Strange0Sarah M. Manchak1Jordan M. Hyatt2Damon M. Petrich3Alisha Desai4Cory P. Haberman5Department of Sociology and Criminology, Criminal Justice Research Center Pennsylvania State University University Park Pennsylvania USAUniversity of Cincinnati School of Criminal Justice Cincinnati Ohio USADepartment of Criminology and Justice Studies Drexel University Philadelphia Pennsylvania USAUniversity of Cincinnati School of Criminal Justice Cincinnati Ohio USADepartment of Psychology Drexel University Philadelphia Pennsylvania USAUniversity of Cincinnati School of Criminal Justice Cincinnati Ohio USAAbstract Background The overlap between justice system involvement and drug use is well‐documented. Justice‐involved people who misuse opioids are at high risk for relapse and criminal recidivism. Criminal justice policymakers consider opioid‐specific medication‐assisted therapies (MATs) one approach for improving outcomes for this population. More research is needed that explores the impacts of opioid‐specific MATs for justice‐involved people. Objectives This study sought to assess the effects of opioid‐specific MAT for reducing the frequency and likelihood of criminal justice and overdose outcomes for current or formerly justice‐involved individuals. Search Methods Records were searched between May 7, 2021 and June 23, 2021. We searched a total of sixteen proprietary and open access databases that included access to gray literature and conference proceedings. The bibliographies of included studies and relevant reviews were also searched. Selection Criteria Studies were eligible for inclusion in the review if they: (a) assessed the effects of opioid‐specific MATs on individual‐level criminal justice or overdose outcomes; included (b) a current or formerly justice‐involved sample; and (c) a randomized or strong quasi‐experimental design; and c) were published in English between January 1, 1960 and October 31, 2020. Data Collection and Analysis We used the standard methodological procedures as expected by The Campbell Collaboration. Main Results Twenty studies were included, representing 30,119 participants. The overall risk of bias for the experimental studies ranged from “some” to “high” and for quasi‐experimental studies ranged from “moderate” to “serious.” As such, findings must be interpreted against the backdrop of less‐than‐ideal methodological contexts. Of the 20 included studies, 16 included outcomes that were meta‐analyzed using mean log odds ratios (which were reported as mean odds ratios). Mean effects were nonsignificant for reincarceration (odds ratio [OR] = 0.93 [0.68, 1.26], SE = .16), rearrest (OR = 1.47 [0.70, 3.07], SE = 0.38), and fatal overdose (OR = 0.82 [0.56, 1.21], SE = 0.20). For nonfatal overdose, the average effect was significant (OR = 0.41 [0.18, 0.91], SE = 0.41, p < 0.05), suggesting that those receiving MAT had nearly 60% reduced odds of a nonfatal overdose. Implications for Policy, Practice, and Research The current review supports some utility for adopting MAT for the treatment of justice‐involved people with opioid addiction, however, more studies that employ rigorous methodologies are needed. Researchers should work with agencies to improve adherence to medication regimens, study design, and collect more detailed information on participants, their criminal and substance use histories, onset, and severity. This would help clarify whether treatment and control groups are indeed comparable and provide better insight into the potential reasons for participant dropout, treatment failure, and the occurrence of recidivism or overdose. Outcomes should be assessed in multiple ways, if possible (e.g., self‐report and official record), as reliance on official data alone may undercount participants' degree of criminal involvement.https://doi.org/10.1002/cl2.1215
spellingShingle C. Clare Strange
Sarah M. Manchak
Jordan M. Hyatt
Damon M. Petrich
Alisha Desai
Cory P. Haberman
Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
Campbell Systematic Reviews
title Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
title_full Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
title_fullStr Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
title_full_unstemmed Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
title_short Opioid‐specific medication‐assisted therapy and its impact on criminal justice and overdose outcomes
title_sort opioid specific medication assisted therapy and its impact on criminal justice and overdose outcomes
url https://doi.org/10.1002/cl2.1215
work_keys_str_mv AT cclarestrange opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes
AT sarahmmanchak opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes
AT jordanmhyatt opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes
AT damonmpetrich opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes
AT alishadesai opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes
AT coryphaberman opioidspecificmedicationassistedtherapyanditsimpactoncriminaljusticeandoverdoseoutcomes